Article Text

Download PDFPDF

EPV296/#395 ‘A prospective multicentric study of risk-reducing salpingo-oophorectomy in brca mutation patients’
  1. M Spinelli1,
  2. F Arezzo2,
  3. G Sicolo3,
  4. CM Santarsiero3,
  5. V Loizzi4,
  6. G Cazzato5,
  7. L Resta5,
  8. G Serio5,
  9. G Cormio6,
  10. E Cicinelli7 and
  11. I Romagno2
  1. 1Policlinico of Bari, Obstetrics and Gynecology Department, Bari, Italy
  2. 2Policlinico of Bary, Obstetrics and Gynecology Department, Bari, Italy
  3. 3university of Bari Aldo Moro’, Biomedical Sciences and Human Oncology Obtetrics and Gynecology Unit, BARI, Italy
  4. 4University of Bari ‘Aldo Moro’, Interdisciplinar Department of Medicine, Bari, Italy
  5. 5university of Bari Aldo Moro’, Emergency and Organ Transplantation, Pathology Section, BARI, Italy
  6. 6University of Bari ‘Aldo Moro’, Department of Biomedical Sciences and Human Oncology, Bari, Italy
  7. 7University of Bari ‘Aldo Moro’, Department of Biomedical Science and Human Oncology, Gynecology and Obstetrics Section, Bari, Italy


Objectives BRCA1/2 are tumour-suppressor genes involved in DNA homologous recombination and ovarian cancer development.

Methods Risk-reducing surgery (RRS) was performed in 148 patients carrying BRCA1 (aged between 30–73 years, median age was 51 years) and BRCA 2 mutation (aged between 36–70 years, median age was 53 years). Seventy-nine patients had previous history of breast cancer.

Results Between the all patients, 131 women underwent risk-reducing salpingo-oophorectomy (RRSO) through a laparoscopic minimally invasive approach, 11 (7,4%) underwent laparoscopic RRSO and contextual hysterectomy, 2 woman (1,3%) underwent RRSO through a laparotomic approach and 12 women (8,1%) laparotomic RRSO and hysterectomy. During 7 (4,7%) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complication occurred in 4 patients (3%). Six patients (4%) were found to have occult Serous Tubal Intraepithelial Carcinoma (STIC) and seven patients (4,7%) occult cancer.

Conclusions RRSO is safe and feasible in BRCA mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.